BioNTech SE (ADR)
General ticker "BNTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $25.8B (TTM average)
BioNTech SE (ADR) follows the US Stock Market performance with the rate: 20.4%.
Estimated limits based on current volatility of 1.8%: low 95.97$, high 99.54$
Factors to consider:
- Total employees count: 1310 as of 2019
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [69.57$, 129.81$]
- 2025-12-31 to 2026-12-31 estimated range: [64.86$, 122.52$]
Financial Metrics affecting the BNTX estimates:
- Negative: with PPE of -37.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 86.16 > 63.39
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of -2.92
- Positive: Inventory ratio change, % of -0.53 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 0.33 < Operating cash flow per share per price, % of 0.80
Short-term BNTX quotes
Long-term BNTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 |
|---|---|---|
| Operating Revenue | €3,819.00MM | €2,751.10MM |
| Operating Expenses | €3,128.60MM | €4,065.40MM |
| Operating Income | €690.40MM | €-1,314.30MM |
| Non-Operating Income | €495.70MM | €636.60MM |
| Interest Expense | €7.76MM | €13.16MM |
| R&D Expense | €1,783.10MM | €2,254.20MM |
| Income(Loss) | €1,186.10MM | €-677.70MM |
| Profit(Loss)* | €930.30MM | €-665.30MM |
| Stockholders Equity | €20,245.90MM | €19,411.10MM |
| Inventory | €357.70MM | €283.30MM |
| Assets | €23,006.30MM | €22,529.70MM |
| Operating Cash Flow | €5,371.40MM | €207.70MM |
| Capital expenditure | €705.50MM | €452.30MM |
| Investing Cash Flow | €-6,954.50MM | €-2,081.20MM |
| Financing Cash Flow | €-778.60MM | €-45.90MM |
| Earnings Per Share** | €3.87 | €-2.77 |
| Ordinary share to ADR | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.